• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Sentien launches trial for drug-device combo for treating acute kidney injury

April 19, 2017 By Fink Densford

Sentien Biosciences LogoSentien Biotechnologies said this week it received an Investigational New Drug approval for its SBI-101 drug-device combination product meant for treating individuals with acute kidney injury.

The multi-center, Phase 1/2 trial will be the the 1st for the company, and will examine its platform which uses a blood filtering device containing mesenchymal stromal cells for the controlled, sustained delivery of MSC secreted factors.

“This marks a very significant milestone for our company as we move our lead product into the clinic. We are motivated and excited by the opportunity to advance SBI-101 into the clinic to treat patients with severe AKI, which represents a significant unmet medical need,” CEO Brian Miller said in a press release.

The 24-patient trial is slated to be a randomized, controlled, multi-dose study in patients with acute kidney injury receiving continuous renal replacement therapy. The study’s primary objective will be to evaluate the safety and tolerability of the drug-device combo, while secondary endpoints will examine efficacy.

Patient enrollment is planned for the 2nd quarter of 2017 and expected to continue through 2018, the company said.

Sentien said earlier this month it closed a $12 million Series A financing round, co-led by Boehringer-Ingelheim Venture Fund USA, Inc. and BioInnovation Capital. Chiesi Ventures, MBL Venture Capital Co. and Mass Medical Angels also contributed to the round.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured Tagged With: Sentien Biotechnologies

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS